CTOs on the Move

CANTEST

www.cantest.com

 
CANTEST Ltd is a Burnaby, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cantest.com
  • 4606 Canada Way
    Burnaby, BC CAN V5G 1K5
  • Phone: 925.924.6000

Executives

Name Title Contact Details

Similar Companies

Family Service Association of Bucks County

Family Service offers a variety of programs and services focused on increasing opportunities for adults, protecting seniors, reducing substance abuse, improving the lives of those with mental illness, preparing children and adolescents for the future, ...

Modern Recovery

[et_pb_section fb_built="1" specialty="on" custom_padding_last_edited="on|tablet" _builder_version="4.6.6" _module_preset="default" background_color="#9e9e9e"

Takeda

For more than 235 years, Takeda has been serving society with innovative medicines, helping patients reclaim valuable moments of life from illness. Now, with new healthcare solutions from prevention to care and cure, we are determined to help even more people enjoy their lives to the fullest. Our mission is simple: we strive toward better health for patients worldwide through leading innovation in medicine. This mission: • Drives our research and development of prescription drugs • Promotes our commitment to social responsibility • Marks our growth and success At Takeda, our passion for healthcare and commitment to improving lives will enable us to make the next 230 years healthier and brighter for people around the world. Our robust product pipeline is focused on treating serious diseases and disorders, including bone and joint disorders, cardiovascular disease, central nervous system disorders, chronic kidney disease, diabetes, gastroenterology, gynecological disorders and infectious disease.

LucidHealth

Infrastructure, technology & strategic resources by radiologists, for radiologists.

Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix`s proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus.